Premium
Posaconazole delayed‐release tablets in paediatric haematology–oncology patients
Author(s) -
Mauro Margherita,
Colombini Antonella,
Perruccio Katia,
Zama Daniele,
D'Amico Maria Rosaria,
Calore Elisabetta,
Carraro Francesca,
Muggeo Paola,
Tridello Gloria,
Baretta Valentina,
Cesaro Simone
Publication year - 2020
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.13084
Subject(s) - posaconazole , medicine , pharmacokinetics , hematology , surgery , antifungal , dermatology , voriconazole
Summary Background To date, there are few studies that describe pharmacokinetics, safety and efficacy of posaconazole delayed‐release tablet (DRT) formulation in the paediatric population. Objectives We evaluated retrospectively posaconazole plasma concentrations and safety of posaconazole DRT in paediatric haematology–oncology patients. Patients and methods Posaconazole DRT was assessed in 28 haematological paediatric patients with a median age 15 of years (range 5‐18) and a median body weight of 50 kg (range 22‐83 kg). Twenty‐one patients received posaconazole DRT as prophylaxis and 7 patients as therapy. Results As prophylaxis, the median daily dose was 5.5 mg/kg/day (range 2.2‐22.2) with posaconazole trough level ≥ 0.7 μg/mL in 80% by first week, 62.5% by second week and 87.5% by fourth week. As therapy, the median daily dose was 4 mg/kg/day (range 3.3‐4.5) with trough level ≥ 1 μg/mL 100% by first week, 80% by second week and 33.4% by fourth week. Conclusions Posaconazole DRT is feasible in paediatric patients capable to swallow tablets. Specific pharmacokinetic studies are needed.